Palm Beach, FL – December 8, 2020 – The psychedelics drugs market has seen a surge in popularity over the past decade in the U.S. Psychedelics have been familiarly involved with healing and mental treatment practices with mind-altering substances since the dawn of time. However, research studies have generally stopped since psychedelic care was banned in the late 1960s. After being relegated to the margins of sincere scientific examination for about five decades, growing researchers and scientists are exploring the therapeutic value of psychedelic drugs and compounds that could be a new treatment option for people with depression. According to Data Bridge Market Research North America psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with the CAGR of 15.8% in the forecast period of 2020 to 2027 and expected to reach USD 6,846.68 million by 2027. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Active companies in the markets this week include: Mind Cure Health Inc. (OTCQB: MCURF) (CSE: MCUR), Johnson & Johnson (NYSE: JNJ), MindMed (OTCQB: MMEDF) (NEO: MMED), COMPASS Pathways plc (NASDAQ: CMPS), Field Trip Heath Ltd. (CSE: FTRP).
The Data Bridge Market report continued with: “Growing acceptance of psychedelic drugs for treating depression is also increasing market value as the psychedelic drugs has repetitively proven its high rates of effectiveness for treatment for nicotine dependence, alcohol dependence, anxiety associated terminal illness and chronic PTSD as compared to other antidepressants. Currently, different research studies are taking place that are expected to provide a competitive advantage for new and innovative therapeutic manufacturers with competitive psychedelic drugs and methods to develop, define psychedelic drugs, and various other opportunities in the U.S. psychedelic market. Growing acceptance of psychedelic drugs for treating depression across the U.S. is one of the prominent factors for an upsurge demand of psychedelic drugs. Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway named has stated that in the U.S., more than 30 million people are using psychedelic drugs. This factor has increased the research and development activities in psychedelic drugs across the U.S. Hence, this factor has led various pharmaceutical and therapeutic manufactures to shift towards psychedelic drugs. This has further resulted into continuous focus of psychedelic drugs improvement and reduction of side effects associated with psychedelic drugs. Due to these factors, the market is expected to grow at the significant growth rate in the forecast period of 2020 to 2027.”
Mind Cure Health Inc. (CSE: MCUR.CNQ) (OTCQB: MCURF) BREAKING NEWS: WSGF – Mind Cure Announces its Research Program with Psychedelic Compounds – Mind Cure Health Inc is pleased today to announce its translational research program, with an initial focus on psilocybin, ketamine and ibogaine.
These three psychedelic compounds have demonstrated safety profiles with proven efficacy but have not been optimized for medical use. This research program will enable Mind Cure to investigate these compounds for use in pharmaceuticals that treat physical and psychological pain and related mental health illnesses.
Translational research is multidisciplinary in nature and involves applying laboratory research and preclinical studies to develop clinical trials and studies in humans, with the long-term aim of moving scientific discoveries quicker and more effectively.
With this announcement, Mind Cure begins executing on its groundbreaking approach to expedite research and development programs in psychedelic compounds and methodologies. Mind Cure is focused on delivering validation of commercially viable medicines, methods and tools to address the numerous priorities in treating mental health and building upon the current landscape of research in psychedelic compounds, which have largely been studied for psychiatric medicine to date.
Mind Cure’s research into pain will holistically account for the mixed effects of physical pain, psychological pain and the referred and lasting effects on quality of life and clinical outcomes in patients. “Pain transcends all health conditions and, in many ways, contributes significantly to secondary complications, some of which continue throughout a person’s lifetime,” stated Dr. Ryan Hartwell. “Despite social stigmas, many classical psychedelics have safely demonstrated profound therapeutic effectiveness with alleviating all forms of pain associated with neurological trauma and chronic diseases. We begin our research with tremendous promise for new medicines that share structural similarities with improved receptor targeting, dosing, and therapeutic profiles.”
Currently, a variety of drugs are used to manage pain, resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain). Most of these drugs act by binding to protein targets on cell membranes and affecting biochemical processes of the body. The need for better drugs to treat all types of pain is only increasing. One specific area of pain treatment Mind Cure is pursuing is headaches. The global migraine drug market is expected to reach USD 3.51 billion by 2026 at a CAGR of 13.3% from the 2018 data.
Psychoactive properties of ibogaine have been known for decades, and more recently, experimental data from animals and anecdotal reports in humans has shown ibogaine to possess anti-addictive effects. “Ibogaine has tremendous potential,” said Hamilton Morris, who serves on Mind Cure’s scientific advisory board. “It has an incredibly complex pharmacology and that’s just what is currently known, there is still a great deal of research to be done with ibogaine and as well as related alkaloids and synthetic derivatives.”
With respect to ketamine, it has become one of the most promising and exciting neuroprotective agents and therapeutic medicines following neurological and cerebral trauma, and psychiatric conditions such as depression and PTSD. Both ketamine and ibogaine are listed in Canada on the Prescription Drug List and can be administered with a prescription. Recently, psilocybin cubensis has received exemption for medical use.
“We have built a world-class team of scientific minds, and one with a remarkable multi-disciplinary approach to treating mental health,” stated Mind Cure President and CEO Kelsey Ramsden. “Under the leadership of Dr. Hartwell, research using these first three psychedelic compounds is just the beginning. Our focus is on bringing treatment to market with speed and rigor, as such these compounds make the utmost strategic and tactical sense due to their proven efficacy and alignment with the areas of mental health that we are focused on.” To read this and more news for Mind Cure Health, please visit https://www.financialnewsmedia.com/news-mcur/
Other recent developments in the markets include:
Johnson & Johnson (NYSE: JNJ) recently announced Spravato has been approved as the first antidepressant for actively suicidal people, as doctors are becoming increasingly concerned about COVID-19’s effect on the mental health of Americans.
The Food and Drug Administration approval means the quick-acting nasal spray will be available to people with suicidal thoughts and a plan to put them into action, said Michelle Kramer, vice president of J&J’s U.S. neuroscience medical-affairs unit. That constitutes 11% to 12% of as many as 17 million Americans who have major depressive disorder.
Spravato has been used by about 6,000 people for treatment-resistant depression since its approval in March 2019, Kramer said. J&J’s decision to study it in depressed people actively contemplating suicide bucks a trend among drugmakers who routinely exclude such patients from trials.
MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, recently announced that it is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.
Digital therapeutics are defined as evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease. Pairing digital tools, such as wearables and the latest in machine learning, with psychedelic assisted therapies, can give healthcare providers the ability to optimize and better understand the patient journey and therapeutic outcomes from pre-care through to after-care.
COMPASS Pathways plc (NASDAQ: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, recently announced that it has joined the Psychiatry Consortium, an international collaboration to accelerate drug discovery and development in areas of urgent, unmet medical need.
The Psychiatry Consortium, managed by Medicines Discovery Catapult, is a strategic collaboration of leading medical research charities and pharmaceutical companies focusing on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of people living with mental health conditions. COMPASS Pathways will work alongside Psychiatry Consortium members and academic partners to advance research projects, providing support through access to funding, expertise, and commercialization know-how. The Psychiatry Consortium seeks project proposals from the global psychiatric research community via biannual open calls for applications – the next call for applications will open in January 2021.
Field Trip Heath Ltd. (CSE: FTRP), a global leader in the development and delivery of psychedelic therapies, and WHOOP, the human performance company, recently announced a partnership whereby Field Trip will be using WHOOP Strap 3.0 to measure the biometric effects of Field Trip’s psychedelic therapies.
Field Trip, which is opening Field Trip Health centers across North America and Europe for the delivery of psychedelic therapies, plans to conduct an observational study to assess whether Field Trip’s ketamine-assisted therapies, which have demonstrated significant efficacy in treating mental health conditions such as depression, anxiety and PTSD, translate into improvements in physical health through a variety of biometric measures collected via WHOOP Strap 3.0 including heart rate variability (HRV), resting heart rate, and overall sleep quality. Field Trip procured WHOOP products and access to additional data insights via a research partnership and enterprise program.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Mind Cure Health Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: firstname.lastname@example.org – +1(561)325-8757